Hypoxia is a common feature of solid tumors, and develops because of the rapid growth of
the tumor that outstrips the oxygen supply, and impaired blood flow due to the formation of …

Chemotherapeutic drugs are used to treat advanced stages of cancer or following surgery.
However, cancers often develop resistance against drugs, leading to failure of treatment and …

Hypoxia is a non-physiological level of oxygen tension, a phenomenon common in a
majority of malignant tumors. Tumor-hypoxia leads to advanced but dysfunctional …

Research has indicated that hypoxia profoundly contributes to chemoresistance of
pancreatic cancer (PC), while the precise mechanism has not been fully elucidated. In this …

Multiple myeloma (MM) is the second most common blood cancer. Treatments for MM
include corticosteroids, alkylating agents, anthracyclines, proteasome inhibitors …

Multiple myeloma (MM, plasma cell myeloma) is a malignant hematologic disease
characterized by the clonal proliferation of malignant plasma cells. The treatment of MM has …

Drug resistance remains a leading cause of chemotherapeutic treatment failure and cancer-
related mortality. While some mechanisms of anticancer drug resistance have been well …

Abstract Since Judah Folkman hypothesized in 1971 that angiogenesis is required for solid
tumor growth, numerous studies have been conducted to unravel the angiogenesis process …

Chemotherapy remains the mainstay of treatment in the majority of solid and haematological
malignancies. Resistance to cytotoxic chemotherapy is a major clinical problem and …

For many decades classical anti-tumor therapies included chemotherapy, radiation and
surgery; however, in the last two decades, following the identification of the genomic drivers …